CALR and thrombocytosis disease: Even though the oncogenic mechanism of the CALR mutations is not fully clarified, it appears that the mutations enhance the binding of CALR to the thrombopoietin receptor (TPO-R), resulting in the activation of TPO-R and ensuing megakaryocyte proliferation and thrombocytosis [17,18,19,20].